Redeye provides a research update following the Q4 report recently published by Newbury.
Redeye provides a research update following the Q3 report recently published by Newbury.
Redeye provides a research update following the Q2 report published by Newbury yesterday.
Redeye leaves an initial comment following the Q2 report published by Newbury this morning.
Redeye briefly comments on Newbury's directed share issue.
Redeye leaves a comment following Newbury Pharmaceuticals’ announcement earlier today regarding a new international sales order.
Redeye provides a research update following the Q1 report published by Newbury yesterday.
Redeye leaves an initial comment following the Q1 report published by Newbury this morning.
Redeye provides a research update following the Q4 report published by Newbury yesterday.
Redeye leaves an initial comment following the Q4 report published by Newbury this morning.
Redeye leaves a comment on yesterday’s announcement stating that Newbury has successfully signed a SEK15m loan agreement with independent pr...
Redeye leaves a comment following Newbury’s announcement of a new strategic partnership with a global pharmaceutical company.
Redeye provides a research update following the Q3 report published by Newbury yesterday.
Redeye initiates coverage of Newbury Pharmaceuticals, a hybrid pharmaceutical company focusing on providing specialty and branded products o...
